| |
[摘要]：Hepatitis C virus (HCV) is a major chronic disease and infected individuals are at risk of developing multiple and highly severe liver complications, such as cirrhosis or liver carcinoma. The current standard of care for the treatment of HCV is a combination of pegylated interferon alfa and ribavirin, a poorly tolerated regimen with limiting side effects and low sustained virological response rates in genotype 1-infected patients. Therefore, the exploration of alternative treatment regimens is of utmost importance. Daclatasvir dihydrochloride (BMS-790052) is a novel, small-molecule, first-in-class inhibitor of HCV replication that targets non-structural protein SA (NS5A). It has shown impressive clinical efficacy, high selectivity, picomolar activity and broad genotype coverage in vitro. Daclatasvir is safe and generally well tolerated, and it has a pharmacokinetic profile suggestive of once-daily administration. With its extraordinary potency and non-overlapping resistance profile, daclatasvir has the potential to be an important component in future combination strategies for HCV therapy. |
|
